United Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Does UTHR pay dividends?

Dividend History. United Therapeutics does not pay a dividend on stock, and does not foresee doing so in the immediate future.

What does United Therapeutics Corp do?

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company was founded by Martine A.

What kind of company is United Therapeutics Corporation?

United Therapeutics Corporation is an American publicly traded biotechnology company listed on the NASDAQ under the symbol UTHR. Its mission is to develop novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing.

What kind of medicines does United Therapeutics market?

As of 2017, United Therapeutics markets five medicines with over a dozen new medicines in development. The marketed medicines are Remodulin, Tyvaso, Orenitram and Adcirca for pulmonary arterial hypertension, and Unituxin for neuroblastoma.

Where is United Therapeutics in Silver Spring MD?

The company has regenerative medicine products such as these being developed via xenotransplantation, allogenic recellularization, and autologous bioprinting technologies. United Therapeutics owns a 415,000-square-foot combination laboratory and office building complex in Silver Spring, Maryland.

What kind of paradigm does United Therapeutics use?

United Therapeutics generally develops medicines under a pharmacogenomic paradigm that emphasizes association of clinical trial outcomes with genetic polymorphisms identified from whole genome sequencing of patients enrolled in clinical studies.